#USA #San Francisco #ACROBiosystems #JPMorgan #BIOSeedin

ACROBiosystems Promotes Innovation at the BIOSeedin Summit

On January 11, 2026, in San Francisco, the BIOSeedin Winter Innovation Partnering Summit kicked off ahead of the highly anticipated J.P. Morgan Health Conference. This significant event brought together pharmaceutical giants, investors, and biotech firms, all exploring licensing opportunities and global expansion strategies. With the motto “Global Matching of Innovative Assets,” over 500 delegates engaged in vibrant discussions, focusing on fostering collaboration across the biopharmaceutical landscape. The summit was sponsored by renowned companies including Lilly, Roche, and Fangda Partners.

ACROBiosystems, a crucial strategic partner, reaffirmed its commitment to global medical innovation with its brand promise: “Connecting the world, your partner from discovery to the clinic.” This initiative aims to merge resources, promote partnerships, and drive global innovation, all while maintaining high-quality services and products.

A networking lounge set up by ACROBiosystems allowed for in-depth conversations with industry pioneers in pharmaceuticals and biotech. Discussions primarily revolved around the global expansion of locally developed drugs, including licensing, clinical developments, and market access strategies to optimize resource allocation efficiently.

Industry Spotlight: Global Strategies and Local Innovations

In the dedicated Oncology panel, speakers highlighted China’s unique strengths, particularly regarding clinical speed, platform iteration, and portfolio strategy. The insights shared suggested that competitive innovations in areas like Antibody-Drug Conjugates (ADC), T-Cell Engagers (TCE), and novel cell/gene therapies were on the horizon.

Conversely, the Cardiovascular, Renal, and Metabolic panel discussed how small biotech companies emerged as key innovation drivers, validating that clinical studies have become less risky. Established multinational corporations were seen as leveraging their market advantages, especially within the cardiovascular sector.

In discussions focused on Autoimmune Diseases, panelists shared strategies for establishing First-in-Class (FIC) targets, emphasizing the need for smarter business structures, regional stratification, and global coordination to expedite value creation.

High-profile representatives from global pharmaceutical companies, investment firms, and biotech corporations partook in the sessions. Notable attendees included Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, and several others like Hengrui Pharma and GSK, contributing their insights to the collaborative atmosphere.

Biotechnological firms such as Adagene, EpimAb Biotherapeutics, and Innovative Cellular Therapeutics showcased their pipelines featuring drugs spanning antibodies, bispecifics, and neuro-metabolites, aimed at enhancing patient outcomes globally.

About ACROBiosystems Group

Founded in 2010 and listed publicly in 2021, ACROBiosystems has established itself as a cornerstone of the global biopharmaceutical industry through innovative products and business models. With a presence in 16 cities worldwide and a robust network of long-term partnerships with leading pharma companies and academic institutions, ACROBiosystems is committed to delivering exceptional service and quality. Their product portfolio, which includes recombinant proteins, kits, antibodies, and associated services, is reinforced by comprehensive quality control systems, ensuring readiness for both research and commercial scale production.

As ACROBiosystems continues to develop new technologies and products, the company adds significant value to the global pharmaceutical landscape. It actively supports its partners in expediting drug development, ultimately aiming to enhance global health outcomes.